Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression

Annals of the Rheumatic Diseases

Volumn 72, Issue 5, 2013, Pages 728-735

  Brkic, Zana ^a   Maria, Naomi I ^a   Van Helden Meeuwsen, Cornelia G ^a   Van De Merwe, Joop P ^a   Van Daele, Paul L ^a   Dalm, Virgil A ^a   Wildenberg, Manon E ^b   Beumer, Wouter ^a   Drexhage, Hemmo A ^a   Versnel, Marjan A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Gastroenterology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD14 ANTIGEN; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; INTERFERON; LA ANTIBODY; RHEUMATOID FACTOR; RO ANTIBODY; RO52 ANTIBODY; RO60 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BAFF GENE; CELL LINE; CONTROLLED STUDY; DISEASE ACTIVITY; EULAR SJOGREN SYNDROME DISEASE ACTIVITY INDEX SCORE; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IFI44 GENE; IFI44L GENE; IFIT3 GENE; IFN 1 GENE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; LY6E GENE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MX1 GENE; NEUTROPHIL COUNT; PREVALENCE; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SJOEGREN SYNDROME; UPREGULATION;

ADULT; AGED; ANTIGENS, CD14; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON TYPE I; MALE; MIDDLE AGED; MONOCYTES; PREVALENCE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SJOGREN'S SYNDROME; UP-REGULATION;

EID: 84875958991     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201381     Document Type: Article

References (35)

1. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11:229.
2. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
3. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-33.
4. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006;103:2770-5.
5. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44. (Pubitemid 40663945)
6. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95. (Pubitemid 40530126)
7. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009;10:285-96.
8. Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-36. (Pubitemid 40563172)
9. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002;14:432-6. (Pubitemid 34671244)
10. Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-53. (Pubitemid 28387618)
11. Montoya M, Schiavoni G, Mattei F, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99:3263-71. (Pubitemid 34525306)
12. Le Bon A, Schiavoni G, D'Agostino G, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-70. (Pubitemid 32441598)
13. Oishi A, Miyamoto K, Kashii S, et al. Abducens palsy and Sjogren's syndrome induced by pegylated interferon therapy. Br J Ophthalmol 2007;91:843-4. (Pubitemid 46846670)
14. Ojha J, Bhattacharyya I, Islam N, et al. Xerostomia and lichenoid reaction in a hepatitis C patient treated with interferon-alpha: a case report. Quintessence Int 2008;39:343-8.
15. Onishi S, Nagashima T, Kimura H, et al. Systemic lupus erythematosus and Sjogren syndrome induced in a case by interferon-{alpha} used for the treatment of hepatitis C. Lupus 2010;19:753-5.
16. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71. (Pubitemid 36135394)
17. Jonsson MV, Szodoray P, Jellestad S, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005;25:189-201. (Pubitemid 40884044)
18. Lavie F, Miceli-Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004;202:496-502. (Pubitemid 38456168)
19. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109:59-68. (Pubitemid 34052542)
20. Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006;8:R51.
21. Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol 2008;67:185-92.
22. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008;131(Pt 6): 1455-63. (Pubitemid 351806460)
23. Jacob N, Guo S, Mathian A, et al. B Cell and BAFF dependence of IFN-alpha-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 2011;186:4984-93.
24. Seror R, Ravaud P, Bowman S, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
25. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 2010;13:1369-81.
26. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 2003;17:2474-86. (Pubitemid 38072587)
27. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67. (Pubitemid 39643944)
28. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503. (Pubitemid 40663941)
29. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440-6.
30. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980-9.
31. Gupta RK, Kumar R, Bassett M. Interferon-induced depressive illness in hep C patients responds to SSRI antidepressant treatments. Neuropsychiatr Dis Treat 2006;2:355-8. (Pubitemid 44566711)
32. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001;92 (Suppl):1664-8. (Pubitemid 32939172)
33. Dantzer R, O'Connor JC, Lawson MA, et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011;36:426-36.
34. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol 2011;23:113-21.
35. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25:383-92. (Pubitemid 44354221)